<p>Innovent Biologics Inc. announced that its total product revenue for the full year of 2025 reached approximately RMB11.9 billion, reflecting a year-over-year growth of around 45%. In the fourth quarter of 2025, the company reported product revenue of approximately RMB3.3 billion, marking a strong year-over-year increase. The company also noted that it recognized inventory price adjustments in the fourth quarter for products previously distributed at original prices. This adjustment was primarily attributed to the inclusion of six new drugs in the 2026 National Reimbursement Drug List (NRDL). The financial information provided is based on internal management records and has not been audited or reviewed by external auditors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260204-12014480), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

589720

588860

588250

01801

512290

513700

Reuters

Guotai SSE STAR Brand Name Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

INNOVENT BIO

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue